High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
1. To correlate established risk biomarkers such as cytomorphology obtained from random
periareolar fine needle aspiration ( RPFNA), mammographic breast density, serum
bioavailable estradiol and IGF-1/IGFBP-3 with each other and with 5-10 year Gail risk
estimates. Where available, and with appropriate safe guards to maintain status for
breast cancer susceptibility genes may be included.
2. To determine the relative predictive value of established risk biomarkers for the
development of DCIS and/or invasive cancer.
3. To evaluate potential new breast tissue-based biomarkers including Ki-67, PCNA, ER,
COX-2, aromatase, methylation of key tumor suppressor genes (i.e., RAR, p16, etc),
proteomic patterns in RPFNA and nipple aspirate fluid (NAF), as well as NAF hormone
levels, and correlate them with other risk biomarkers listed in 1.
4. To determine the prevalence of polymorphisms of a panel of genes important in hormone
and xenobiotic metabolism as well as DNA repair and correlate these polymorphisms with
established risk biomarkers listed in 1, as well as with development of DCIS and
5. To maintain contact with this initially identified cohort of high risk women, acquire
demographic data, biologic specimens and data and follow them prospectively for the
Observational Model: Cohort, Time Perspective: Prospective
Prediction of risk for developing breast cancer
develoment of algorithm for predicting risk for developing breast cancer based on random sampling of benign breast tissue.
Carol J Fabian, MD
University of Kansas
United States: Institutional Review Board
|University of Kansas Medical Center||Kansas City, Kansas 66160-7353|